Stocktoria
Humacyte, Inc. HUMA
Humacyte, Inc. (HUMA) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $2.0M at a -2003.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| DYAI | DYADIC INTERNATIONAL INC | 1/9 | — | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
FAQ
Is HUMA financially healthy?
Humacyte, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does HUMA pay a dividend?
No, Humacyte, Inc. does not currently pay a dividend.
How profitable is HUMA?
In FY2025, Humacyte, Inc. had a net margin of -2003.6% and a return on equity of -1313.4%.
What is the analyst price target for HUMA?
The average Wall-Street price target for Humacyte, Inc. is $2.05, about 208.3% above the recent price, from 5 analysts (consensus: buy).
Is HUMA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Humacyte, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.